Suppr超能文献

日本非感染性葡萄膜炎患者的真实世界治疗模式:一项使用大规模索赔数据库的描述性研究(J-CAT研究)

Real-world treatment patterns for patients with non-infectious uveitis in Japan: a descriptive study using a large-scale claims database (J-CAT study).

作者信息

Kusuhara Sentaro, Sonoda Koh-Hei, Kaburaki Toshikatsu, Fujita Tachie, Katayama Saki, Makishima Misako, Nakamura Takao, Nio Mariko, Omoto Takashi, Matsuo-Tezuka Yukari, Yoshizaki Tomoki, Sasaki Kensuke, Ri Kairi, Sato Keiko, Goto Hiroshi

机构信息

Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, 650-0017, Japan.

Department of Ophthalmology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.

出版信息

J Ophthalmic Inflamm Infect. 2025 Jul 22;15(1):56. doi: 10.1186/s12348-025-00514-5.

Abstract

PURPOSE

Non-infectious uveitis (NIU) can arise from various inflammatory disorders and can cause vision loss. Patients with mild NIU are typically treated with corticosteroid eye drops to reduce intraocular inflammation; however, other local/systemic treatments (corticosteroids, immunosuppressants, biologics) may be required for moderate-to-severe NIU, which may cause ocular complications. Here, we investigated real-world treatment patterns for NIU in Japan.

METHODS

Patients were selected from a large, Japanese insurance claims database using International Classification of Diseases, Tenth Revision codes; diagnosis of NIU was confirmed via ophthalmological examination (October 2016-October 2023). Sankey diagrams were used to describe treatment transitions. Post-treatment ocular complications, potentially related surgeries, and fundus findings associated with uveitis were determined.

RESULTS

The majority of patients (68.7%; 37,869/55,091) were treated with corticosteroid eye drops only for mild NIU; 19.0% (10,449/55,091) were given other treatments for moderate-to-severe NIU, mostly oral corticosteroids (7,473/10,449) and posterior sub-Tenon's corticosteroid injections (1,636/10,449). In patients treated with corticosteroids orally or via sub-Tenon's injections, common transitions were to corticosteroid eye drops or censor (end of treatment/dataset or insurance withdrawal). A higher incidence of treatment-related ocular complications and potentially related surgeries (including glaucoma) was observed during the first year of NIU treatment compared with subsequent years (for moderate-to-severe NIU, estimated incidence of prescription of glaucoma drugs was 106 per 1,000 person-years [at 1 year], 73 per 1,000 person-years [at 2 years], and 52 per 1,000 person-years [at 5 years]).

CONCLUSION

Our comprehensive analysis of a large claims database included all prescribed medications and medical procedures (including local injections) for NIU treatment in Japan up to October 2023. Although corticosteroids are a mainstay of NIU treatment in Japan, we found that a number of treatments for moderate-to-severe NIU, other than corticosteroid eye drops, are frequently used in combination with or when switching from corticosteroid eye drops. These findings are of importance when assessing the treatment landscape and may help identify unmet clinical needs in patients with NIU.

摘要

目的

非感染性葡萄膜炎(NIU)可由多种炎症性疾病引起,并可导致视力丧失。轻度NIU患者通常使用皮质类固醇眼药水治疗以减轻眼内炎症;然而,中重度NIU可能需要其他局部/全身治疗(皮质类固醇、免疫抑制剂、生物制剂),这可能会引起眼部并发症。在此,我们调查了日本NIU的实际治疗模式。

方法

使用国际疾病分类第十版代码从一个大型日本保险理赔数据库中选取患者;通过眼科检查(2016年10月至2023年10月)确诊NIU。使用桑基图描述治疗转变情况。确定治疗后眼部并发症、潜在相关手术以及与葡萄膜炎相关的眼底检查结果。

结果

大多数患者(68.7%;37869/55091)仅使用皮质类固醇眼药水治疗轻度NIU;19.0%(10449/55091)的中重度NIU患者接受了其他治疗,主要是口服皮质类固醇(7473/10449)和后Tenon囊下皮质类固醇注射(1636/10449)。在接受口服或Tenon囊下注射皮质类固醇治疗的患者中,常见的转变是改用皮质类固醇眼药水或审查(治疗结束/数据集结束或保险退保)。与随后几年相比,在NIU治疗的第一年观察到与治疗相关的眼部并发症和潜在相关手术(包括青光眼)的发生率更高(对于中重度NIU,青光眼药物处方的估计发生率为每1000人年106例[第1年]、每1000人年73例[第2年]和每1000人年52例[第5年])。

结论

我们对一个大型理赔数据库进行的综合分析涵盖截至2023年10月日本NIU治疗中所有开具的药物和医疗程序(包括局部注射)。尽管皮质类固醇是日本NIU治疗的主要药物,但我们发现,除皮质类固醇眼药水外,许多中重度NIU的治疗方法经常与皮质类固醇眼药水联合使用或在从皮质类固醇眼药水转换治疗时使用。这些发现对于评估治疗情况具有重要意义,可能有助于确定NIU患者未满足的临床需求。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验